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Three novel series were generated in order to mimic the 
pharmacophoric features displayed by lead compound 
AM095, a Lysophosphatidic acid (LPA1) receptor antagonist. 
Biological evaluation of this array of putative LPA1 
antagonists led us to the discovery of three novel series of 
inhibitors of the ecto-enzyme Autotaxin (ATX), responsible 
for LPA production in blood, with potencies in the range 1 ± 
ȝ0DFFRPSDQLHGZLWKJRRG!ȝJP/VROXELOLW\.  
Introduction 
Lysophosphatidic acid (LPA) is a bioactive phospholipid, accessed 
via the hydrolysis of lysophosphatidyl choline (LPC) by the enzyme 
Autotaxin (ATX)1,2 and mediates most of its biological effects 
through a set of six G-protein-coupled receptors (GPCRs) known as 
LPA1-6.
3 These receptors induce a number of downstream signalling 
pathways and exert a range of cellular responses such as calcium 
mobilisation, transformation of smooth muscle cells, cell 
proliferation and migration, prevention of apoptosis, and chemotaxis 
through acting as agonists at membrane-bound GPCRs.4 Based on 
this, the ATX-LPA signalling pathway has been implicated in many 
disease states including cardiovascular disease,5 autoimmune 
disease,6 cancer,7 fibrotic diseases,8 inflammation,9 
neurodegeneration,10 and pain,11 amongst others. Accordingly, 
significant efforts have been invested in the generation of novel lead 
compounds in order to identify new chemotypes for the treatment of 
LPA/ATX-related disorders. A recent review has summarised the 
current state of lysophospholipid receptors in drug discovery.12 
Among the first LPAR antagonists synthesised were lipid like 
structures,13,14 similarly the first patent describing ATX inhibitors 
were also lipid-like.15 As both LPA1 and ATX bind LPA, one might 
expect a degree of cross-talk between the types of compound which 
interact with both targets. This phenomenon has been reported with 
syn- and anti- diastereomers of Į-bromophosphonates (BrP-LPA); 
pan-LPA1-3 antagonists and nanomolar inhibitors of ATX.
16 
However, these lipid-like compounds are suboptimal drug 
development candidates, as their physicochemical profiles do not 
meet conventional medicinal chemistry requirements, as they exhibit 
high molecular weight and lipophilicity, two factors which are 
associated with attrition in drug development.17 The first non-lipid 
like structure acting as an LPA receptor antagonist was Ki16425.18 
This was identified through screening of 150,000 low molecular 
weight compounds by the Kirin Brewery for LPA receptor 
antagonism. It was found that the isoxazole derivative Ki16425(1) 
inhibited LPA-induced actions in a manner highly specific to LPA1 
and LPA3 receptor subtypes.
18  Subsequently, AM095(4), a novel  
LPA1 receptor antagonist originally developed by Amira 
Pharmaceuticals Inc., and accompanied by Bristol-Myers Squibb, 
was developed. Further classes of LPA1 receptor antagonists have 
been disclosed, most recently from Hoffmann-La Roche.3 In order to 
identify novel LPA1-selective antagonists, Hoffmann-La Roche 
undertook a bioisostere approach based on the AM095 scaffold, and 
reported the synthesis and biological testing of a novel class of LPA1 
antagonists.3 Of the reported chemotypes, AM095 has progressed to 
clinical trials and as a result became the main focus of our current 
study. Herein, we report the design and synthesis of a novel palette 
of compounds, derived from the AM095 chemotype which display 
inhibitory activity in the ATX/LPA pathway. 
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Figure 1. Selected LPA1 antagonists 1-4, ATX inhibitor 5, and pan-
LPA1-3 antagonist/ATX inhibitor 6 
Compound Design and Synthesis 
The medicinal chemistry strategy implemented was a scaffold 
hopping approach in order to identify a new chemotype based on the 
Amira (AM095) and Hoffmann-La Roche assets which belong to the 
same pharmacophore. To this end, three unique series were designed 
by performing simple disconnections to give the acyl aniline, the 
aryl indole, and the hydantoin series, removing the isoxazole as it 
was assumed to be a non-essential spacer, as illustrated in Scheme 1. 
The acyl aniline and the hydantoin series retained the carbamate, 
biphenyl acetic acid moieties present in AM095 whilst the aryl 
indole series challenged this binding hypothesis with the 
construction of a series containing a similar structural overlap but 
different functionalities.  In addition to the representative examples 
depicted, the regiochemistry of the biaryl and acetic acid moiety 
would be probed. The aim of the three series was to design a 
³UHGXFHG FRPSOH[LW\¶ OHDG-like)19 library using simple synthetic 
handles available for chemical synthesis.  
 
In order to qualitatively asses the level of similarity between AM095 
and the three proposed series, a range of overlays were prepared 
using energy minimized structures of AM095 and an exemplar from 
each series. These were generated using Gaussian20 programme and 
then manually overlayed using Discovery Visualiser,21 as efficient 
overlap may be indicative of a similar binding mode. These novel 
heterocyclic biaryl compounds could potentially provide selectivity 
toward LPAR isoforms. Based on the analysis shown in Scheme 1 
all compounds demonstrated a reasonable degree of overlap with 
AM095, and accordingly, these templates were prioritised for 
synthesis in order to validate their biological properties against both 
LPA receptors and Autotaxin. 
 
The synthetic approach used for the construction of the acyl aniline 
and the aryl indole series is illustrated in Schemes 2 and 3, 
respectively.  The acyl aniline series was divided into three main 
routes in order to probe: (i) the position of the acetic acid moiety; (ii) 
the presence of the acetic acid moiety; and (iii) the potential for 
functionalization on the nitrogen of the aniline in the form of a 
cyclohexyl (c-Hex) or a tetrahydropyran (THP) group to mimic the 
isoxazole group present in AM095.The synthetic route associated 
with each of these three subgroups involved the use of three main 
steps: (i) carbamate formation; (ii) Suzuki-Miayura cross-coupling; 
and (iii) hydrolysis. Compounds 7, 16, and 17 were synthesised by 
reaction of 3-bromoaniline with benzyl chloroformate to afford 
carbamate 11, which could then be taken forward into the Suzuki-
Miayura cross-coupling, using a range of substituted pinacol boronic 
esters to install the desired biaryl functionality. 
Scheme 1. Schematic representation of the three proposed series (7-
9) from disconnecting AM095 and their corresponding overlays with 
AM095 (grey).  
 
The final step involved the hydrolysis of the ester moiety to afford 
the desired acetic acid compounds. A similar route was followed for 
the formation of compound 15, which involved the reaction of 
phenyl boronic acid with compound 11 in order to obtain the biaryl 
species lacking the acetic acid moiety. Lastly, substitution was 
introduced on the nitrogen of the aniline by reductive amination of 
10 with cyclohexanone and tetrahydropyranone, followed by the 
carbamate formation using benzyl chloroformate, and, finally, 
hydrolysis to reveal the acetic acid moiety for compounds 25 and 26. 
 
 
Scheme 2. Route developed for the synthesis of acyl aniline 
compounds. a) K2CO3, CbzCl, 2-MeTHF, rt, 5 h; b) ¶-
(dimethylamino)-2-biphenylyl-palladium(II)chloride 
dinorbornylphosphine complex, K3PO4, pinacol boronic ester, 1,4-
dioxane/water (2:1), 130 &PLQȝ:; c) NaOH, THF, 16 h, 40 
°C. 
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Scheme 3. Route developed for the synthesis of the substituted acyl 
aniline compounds. a) NaHB(OAc)3, DCE, AcOH, rt, 24 h, 
cyclohexanone or tetrahydropyranone; b) K2CO3, CbzCl, DCE, rt, 24 
h; c) ¶-(dimethylamino)-2-biphenylyl-palladium(II)chloride 
dinorbornylphosphine complex, K3PO4, pinacol boronic ester, 1,4-
dioxane/water (2:1), 130 &PLQȝ:; d) NaOH, THF, 16 h, 40 
°C. 
 
A similar route was undertaken for the synthesis of the aryl indole 
compounds, illustrated in Scheme 4. However, hydrolysis of the 
benzylic ester to the acetic acid was performed prior to the 
introduction of the carbamate.  
 
 
Scheme 4. Route developed for the synthesis aryl indole 
compounds. a) ¶-(Dimethylamino)-2-biphenylyl-
palladium(II)chloride dinorbornylphosphine complex, K3PO4, 
pinacol boronic ester, 1,4-dioxane/water (2:1), 130 &PLQȝ:; 
b) NaOH, THF, 40 °C, 16 h; c) NaH, DMF, N-
(Benzyloxycarbonyloxy)succinimide, 40 °C, 16 h. 
 
The hydantoins series was accessed via two main routes (i) benzyl 
hydantoin, and (ii) pyridyl hydantoin. The phenyl substituted 
hydantoin possessed good structural overlay with AM095, therefore 
the isopropyl (i-Pr) and cyclohexyl (c-Hex) groups were designed as 
isosteres to the phenyl group with the goal of lowering clogP and 
reducing the number of aromatic rings to below three.22 Within the 
benzyl hydantoin the presence/absence of the acetic acid would be 
probed along with cyclopropyl substitution alpha to the carboxylic 
acid. The synthetic route applied to the hydantoin series is illustrated 
in Schemes 5 and 6. The construction of this series required firstly 
the synthesis of the requisite hydantoin intermediates using reductive 
amination, of both 2-(4-bromophenyl)acetaldehyde and 5-bromo 
picolinaldehyde to the secondary amines 34 and 43. Preparation of 
the target hydantoins involved the reaction of the appropriate 
secondary amine with the relevant isocyanate system, yielding a urea 
derivative. This derivative is not isolated but can be readily 
converted to the hydantoin following treatment with a protic acid, in 
this case, trifluoroacetic acid. This was applied to the synthesis of 
compounds 35-37 (Scheme 5), and 44-45 (Scheme 6). Suzuki-
Miyaura cross-coupling was used to prepare the biaryl hydantoins 
with boronic pinacol esters and then smoothly hydrolysed to the 
acetic acid functionality, furnishing compounds 9, 38-41 and 46-47.   
Scheme 5. Route developed for the synthesis of the hydantoin 
compounds. a)  Glycine methyl ester hydrochloride, EtOH, NEt3, 
MeOH, NaBH4, rt, 2 h; b) CH2Cl2, isocyanate, TFA; c) Pinacol 
boronic ester, Pd2(dba)3, PCy3, K3PO4, 1,4-dioxane/H2O (1.3:0.7), 
100 °C, 16 h; d) THF/H2O (3:1), LiOH, rt, 3 h. 
 
Scheme 6. Route developed for the synthesis of the pyridine 
hydantoin compounds. a) Glycine methyl ester hydrochloride, 
MeOH, NEt3, NaBH(OAc)3; b) CH2Cl2, isocyanate, TFA; c) ¶-
(dimethylamino)-2-biphenylyl-palladium(II)chloride 
dinorbornylphosphine complex, K3PO4, 4-(carboxymethyl)
phenylboronic acid pinacol ester,  1,4-dioxane/water (2:1), 100 °C, 
16 h; d) THF/H2O (3:1), LiOH , rt,  3 h. 
Pharmacology 
 
The synthesised compounds were evaluated for both LPA1 receptor 
agonism and antagonism using CHO-.('*ȕ-Arrestin cell line 
in a single dose format (10 µM), with the inclusion of 1-oleoyl- 
LPA, AM095, and Ki16425 as controls.23 The data obtained from 
the assay is described in terms of a percentage of agonism where 
100% refers to complete agonism and 0% refers to complete 
antagonism. The data obtained from this assay unfortunately 
indicated that none of the synthesised compounds were acting as 
LPA agonists, and in terms of antagonist activity only the controls, 
1-oleoyl-LPA, AM095 (11% activity) and Ki16425 (16% activity), 
showed clear LPA1 antagonism. From the design strategy of our 
novel series we speculated that the isozaxole of AM095 was a spacer 
between an essential carbamate and biaryl acetic acid moieties. From 
this data it is now clear that isoxazole replacement is not tolerated in 
terms of LPA1 antagonism within this chemotype. However, it can 
be derivatized, as demonstrated by Qian et al triazole and pyrazole 
analogues.3 In parallel, the three series were evaluated for ATX 
inhibitory activity with bis-(p-nitrophenyl) phosphate as the 
substrate and PF-8380, a known ATX inhibitor,24 as the standard for 
comparison. As well as generating key developability data,28 
(logD,25 solubility,26 and permeability27) concentration-response (1 
nM - 30 µM) studies were performed to determine the potency of all 
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compounds against ATX.28 The inhibitor constants (Ki) are 
summarized in Tables 1-4. To enable comparison with our 
progenitor hit compounds AM095 and Ki16245 were also tested as 
ATX inhibitors at 30 µM and showed less than 20% ATX inhibition. 
Pleasingly, it was found that several of the compounds tested 
exhibited Ki values less than ȝ0 (7-9, 20, 27, 34, 35, 37, 38, 43, 
and 44). The active compounds were all equipotent, however, varied 
significantly in their physicochemical profiles; solubility was 
generally high (>100 µg/mL), as measured by a high throughput 
solubility assay. However, permeability varied between the series, 
with the acyl aniline and indole compounds exhibiting increased 
membrane permeability, compared to those in the hydantoin series.   
From the acyl aniline series it became evident that the presence of 
the acetic acid moiety was essential as its removal in compound 15 
caused a complete loss of activity compared to compounds 7, 16, 
and 17. The acetic acid moiety is potentially binding to the Zn2+ ions 
present in the active site of ATX, an interaction that has been noted 
with other acidergic groups.29 An additional set of overlays were 
conducted, as illustrated in Scheme 7, with compounds 7, 15, 16 and 
17 in order to rationalise the biological data which implied that the 
position of the acetic acid (-o, -m, or -p) is not important, however, 
its presence is essential for activity. The overlay diagrams indicated 
that the backbone of all four compounds contained the same 
conformation. In terms of the three acetic acid moieties these all 
pointed in the same spacial orientation, indicating the potential 
beneficial interaction within the catalytic pocket. This would further 
support why its removal led to a complete loss of activity. 
 
Scheme 7. Overlaid diagram of compounds 7 (blue), 15 (purple), 16 
(red), and 17 (green) to illustrate the position of the acetic acid 
moiety. 
It was also noted that substitution on the nitrogen of the aniline was 
tolerated, as illustrated by compound 25, with the introduction of a 
cyclohexyl group, and resulted in a Ki RI  ȝ0 +RZHYHU WKH
introduction of the tetrahydropyran (THP) group, compound 26, in 
this position was inactive , perhaps suggesting an unfavourable polar 
interaction with the oxygen present in the THP group which is 
absent in the cyclohexyl group. Thus, implying that other polar 
functionalities may also not be tolerated in this position.  
 













15 H - H > 30 7.52 5 450 
16 H 1 CH2CO2H 4 3.06 287 140 
17 H 2 CH2CO2H 3.5 3.10 221 64 
7 H 3 CH2CO2H 4.5 3.19 198 73 
aCompound Number (Cpd), bChromlogD at pH 7.4 (LogD), 
cChemiluminescent nitrogen detection (CLND) kinetic aqueous 
solubility assay (Sol.), dPermeability pH 7.4 assay (Papp). 
 
Table 2. Biological and Physicochemical Data for Substituted Acyl 
Aniline Series. 






25 c-Hex 2 4.92 189 150 
26 THP >30 3.13 212 23 
 
The aryl indole compounds, however, illustrated that the substitution 
of the biaryl ring was in fact important as moving the aryl carbamate 
from the 5 to the 6 position led to inactivity with Ki values of 1.1 
DQG!ȝ0, respectively. Strikingly, this data implies that the acid 
moiety which was previously believed to be essential for activity is 
in fact not important therefore indicating a potential alternative 
hydrophobic binding mode. 
 
Table 3. Biological and Physicochemical Data for Aryl Indole Compounds. 









8 5 1.1 7.25 70 445 
32 6 >30 7.43 110 510 
aCompound Number (Cpd). bChromlogD at pH 7.4 (LogD). 
cChemiluminescent nitrogen detection (CLND) kinetic aqueous 
solubility assay (Sol.). Permeability pH 7.4 assay (Papp). 
Lastly, within the third series, phenyl substituted hydantoins with the 
presence or absence of an acetic acid moiety were active, 38 and 39 
1.3 and 3.6 µM, respectively, potentially indicating a different 
binding mode to both the acyl aniline and the aryl indole series. 
Surprisingly however, the addition of a cyclopropyl group adjacent 
to the acid group 36 rendered the compound inactive, potentially 
suggesting an unfavourable steric clash within the active site of the 
constrained and bulky cycloproply group.  The isopropyl and 
cyclohexyl substituted hydantoins (40, 41, 46, and 47) all showed 




Table 4. Biological and Physicochemical Data for Hydantoin Series 









38 Ph C H 1.3 6.24 7.5 540 
9 Ph C CH2CO2H 3.6 2.18 174.5 3 
39 Ph C C(c-propyl) >30 1.50 195 16 
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CO2H 
40 i-Pr C CH2CO2H 1.2 1.10 190 3 
41 c-Hex C CH2CO2H 1.8 1.12 185.5 22 
46 i-Pr N CH2CO2H 4 -1.38 108 <10 
47 c-Hex N CH2CO2H 3.9 -0.35 93 <30 
aCompound Number (Cpd), bChromlogD at pH 7.4 (LogD), 
cChemiluminescent nitrogen detection (CLND) kinetic aqueous 
solubility assay (Sol.), dPermeability pH 7.4 assay (Papp). 
To examine whether the inhibitors had an impact upon in-cell 
proliferation via ATX modulation, three of the prepared ATX 
inhibitors (7, 25, and 38) and AM095 were examined using a [3H]-
thymidine incorporation assay where the quantity of tritiated 
thymidine measured is proportional to DNA synthesis, as illustrated 
in Figure 2. There was a significant increase in DNA synthesis 
within PC3 cells when stimulated with LPA (p<0.05). Upon 
treatment with 7, 25, and 38 as well as AM095, DNA synthesis was 
inhibited to a statistically significant level (p<0.05) with respect to 
the control. Compounds 7, 25, 38 show ATX inhibitory potency and 
block baseline [3H]-thymidine incorporation into PC3 cells, this 
suggests that the inhibitory effect is due to the compounds blocking 
the endogenous production of LPA by ATX. This can be rationalised 
by the fact that PC-3 cells express significant levels of endogenous 
autotaxin30 that drives the generation of lysophophatidic acid (LPA) 
which in turn provides an autocrine / paracrine feedback loop to 
drive basal proliferation of these cells.  Visual inspection of the cells 




3H-thymidine incorporation into LPA (2 µM), AM095 
(graph a), compound 7 (graph b), compound 25 (graph c), or 
compound 38 (graph d) (10 µM), stimulated  prostate cancer (PC3) 
cell line, cells were quiesced for 24 hours and treated for 18 hwith 
compounds (AM095, 7, 25, or 38). n=9, data represented as 
Mean±S.E.M 
Compounds 7, 25, and 38 were also tested for cytotoxicity in an 
A2780 ovarian cancer cell line at 30 µM using an Alamar Blue® 
Assay. Gratifyingly, none of the compounds showed any signs of 
cytotoxicity.   
Conclusions 
Using a range of literature templates as a basis to design new 
compounds which could interact in the LPA-ATX signalling 
pathway, three novel chemotypes have been prepared and their 
inhibitor activities at LPA and ATX have been assessed. 
Although the compounds prepared did not show any activity 
against the LPA1 receptor, cross screening against ATX 
revealed that several exemplars had significant levels of 
inhibitory activity against the enzyme. Allied to this, 
measurements of the key developability parameters indicated 
that several of the hits identified had promising 
physicochemical profiles, suggesting that the series identified 
could offer potential for further optimisation. Efforts to achieve 
this are on-going and will be reported in due course.  
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